ARTICLE | Management Tracks
Broadhurst, Hait, Mammen and Swanson added to J&J’s executive committee
Plus: Vertex vet Holmlund joins Lyndra and updates from Adial, TrialSpark and more
December 10, 2021 3:04 AM UTC
On the heels of announcing that Joaquin Duato will become CEO Jan. 3 and CSO Paul Stoffels will retire, Johnson & Johnson (NYSE:JNJ) appointed four of its senior leaders to its executive committee: Vanessa Broadhurst, Bill Hait, Mathai Mammen and James Swanson.
Broadhurst, company group chairman, global commercial strategy organization, has been appointed EVP, global corporate affairs. Hait, global head of Johnson & Johnson external innovation, is now EVP, chief external innovation, medical safety and global public health officer. Mammen, global head of R&D at the Janssen Pharmaceutical Cos., becomes EVP, pharmaceuticals, R&D. And Chief Information Officer Swanson has been appointed EVP, chief information officer...